Allergan reports $978.7 million in third-quarter product sales

IRVINE, Calif. — Allergan's third-quarter total net product sales increased 23.6% over the same period last year to total $978.7 million, the company announced in a press release.

In the third quarter, eye care pharmaceutical sales increased 13.5% to $457.7 million. Botox (botulinum toxin type A) sales increased 24.8% to $296.7 million compared with the third quarter 2006.

Specifically, in the third quarter, Alphagan (brimonidine tartrate), Alphagan P (brimonidine tartrate 0.15%) and Combigan (0.2% brimonidine tartrate, 0.5% timolol maleate) sales increased 12.2% to $89.8 million, Lumigan (bimatoprost) sales increased 16.2% to $100.4 million and Restasis (cyclosporine ophthalmic emulsion) sales increased 27.3% to $88.2 million, all compared with third quarter of 2006.

Also compared with 2006, third quarter sales of other glaucoma products increased 14.8% to $3.9 million. Glaucoma product sales increased 5% to $11.4 million for the first 9 months of 2007.

For the first 9 months of 2007, net product sales totaled $2.8 billion, with eye care pharmaceutical sales increasing 12.9% to $1.3 billion, Botox sales increasing 23% to $872 million, Alphagan, Alphagan P and Combigan product sales increasing 10.6% to $244.8 million, Lumigan sales increasing 17.8% to $284 million and Restasis sales increasing 21.4% to $243.9 million compared with the same period 2006, according to the release.